Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vaccine trains immune system to fight HPV-Positive head and neck tumors

NCT ID NCT06797986

Recruiting now Disease control Sponsor: Cellid Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests a vaccine called BVAC-E6E7 in people with head and neck cancer linked to HPV types 16 or 18 that cannot be removed by surgery or has spread. The vaccine is designed to teach the immune system to attack cancer cells. The study first checks safety and the best dose, then measures whether the vaccine can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BVAC-E6E7 (a therapeutic vaccine)
What this could lead to
If successful, this vaccine could offer a new treatment option for people with advanced HPV-related head and neck cancer, potentially shrinking tumors and extending survival.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The vaccine may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma human papilloma virus infection human papillomavirus-related squamous cell carcinoma oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HPV (HUMAN PAPILLOMAVIRUS)-ASSOCIATED CARCINOMA HPV-POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seoul National Univesity Hospital

    RECRUITING

    Seoul, South Korea

  • Sevrance Hospital

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.